fallopian tube carcinoma (Cancer)
Information
- Disease name
- fallopian tube carcinoma
- Disease ID
- DOID:1963
- Description
- "A fallopian tube cancer that is located_in the fallopian tube." [url:http\://www.cancer.gov/dictionary/?CdrID=45687]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT04204811 | Active, not recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | December 16, 2019 | December 16, 2024 | |
| NCT01116648 | Active, not recruiting | Phase 1/Phase 2 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | April 14, 2010 | February 13, 2025 |
| NCT02345265 | Active, not recruiting | Phase 2 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | May 23, 2016 | August 9, 2024 |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT02125513 | Active, not recruiting | Phase 2 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer | January 2014 | December 2023 |
| NCT04257045 | Active, not recruiting | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | August 21, 2019 | April 30, 2024 | |
| NCT02124421 | Active, not recruiting | Phase 2 | HOT: HIPEC in Ovarian Cancer as Initial Treatment | April 2014 | April 2028 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT00060359 | Completed | Phase 1 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | April 2003 | |
| NCT01118052 | Completed | Phase 2 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | November 1, 2010 | July 16, 2016 |
| NCT01139957 | Completed | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | June 7, 2010 | April 10, 2020 | |
| NCT01295489 | Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | March 2011 | ||
| NCT01381861 | Completed | Phase 2 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | July 2011 | December 2013 |
| NCT01519869 | Completed | Phase 2 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | March 2012 | October 11, 2019 |
| NCT01709487 | Completed | Phase 1/Phase 2 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | May 2010 | October 2015 |
| NCT01097746 | Completed | Phase 2 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 14, 2010 | September 13, 2022 |
| NCT00066456 | Completed | Phase 1 | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2003 | |
| NCT00301756 | Completed | Phase 2 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | September 2006 | December 2012 |
| NCT00352300 | Completed | Phase 1 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | June 2006 | |
| NCT00499252 | Completed | Phase 2 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | June 2007 | |
| NCT00814086 | Completed | Phase 1 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | February 2009 | |
| NCT00880360 | Completed | Phase 2 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer | February 2007 | April 2010 |
| NCT00939809 | Completed | Phase 2 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 2009 | |
| NCT02118285 | Completed | Phase 1 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | July 28, 2014 | November 12, 2015 |
| NCT02166905 | Completed | Phase 1/Phase 2 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | October 10, 2014 | August 20, 2020 |
| NCT02199171 | Completed | Phase 1 | Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer | July 2014 | October 2017 |
| NCT02315469 | Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | February 10, 2015 | February 9, 2019 | |
| NCT02788708 | Completed | Phase 1 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | May 27, 2016 | March 31, 2022 |
| NCT03297489 | Completed | Early Phase 1 | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer | November 6, 2017 | February 15, 2021 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT01445275 | Not yet recruiting | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | January 2100 | ||
| NCT05406674 | Recruiting | Phase 2 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer | June 15, 2022 | December 2024 |
| NCT06290193 | Recruiting | Phase 2 | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery | February 23, 2024 | February 23, 2029 |
| NCT03296826 | Recruiting | Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 | November 8, 2017 | March 31, 2032 | |
| NCT06299163 | Recruiting | Phase 1 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | May 1, 2024 | December 31, 2027 |
| NCT06420973 | Recruiting | Phase 2 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | May 16, 2024 | September 17, 2027 |
| NCT03604315 | Recruiting | Phase 1 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | December 18, 2018 | June 30, 2027 |
| NCT04834544 | Recruiting | Phase 2 | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care | April 19, 2021 | April 20, 2027 |
| NCT05059444 | Recruiting | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | September 7, 2021 | February 2028 | |
| NCT05763199 | Recruiting | Phase 2 | Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy | December 1, 2023 | July 1, 2027 |
| NCT01773889 | Terminated | Phase 2 | A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer | June 2009 | June 2011 |
| NCT01202890 | Terminated | Phase 1 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | September 2010 | May 2012 |
| NCT01936974 | Terminated | Phase 2 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | September 2013 | August 2015 |
| NCT00968799 | Terminated | N/A | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | February 2008 | December 2012 |
| NCT02033616 | Unknown status | Phase 2 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | November 18, 2017 | March 2023 |
| NCT00958698 | Unknown status | N/A | Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | January 19, 2010 | |
| NCT02344095 | Unknown status | Phase 1 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | December 2014 | October 2015 |
| NCT02328716 | Unknown status | Phase 3 | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma | February 2012 | December 2018 |
| NCT01611766 | Unknown status | Phase 3 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | July 19, 2012 | December 2022 |
| NCT02530606 | Withdrawn | N/A | Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer | September 2016 | November 2018 |
| NCT00551265 | Withdrawn | N/A | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy | October 2007 |
- Disase is a (Disease Ontology)
- DOID:1964
- Cross Reference ID (Disease Ontology)
- MESH:D005185
- Cross Reference ID (Disease Ontology)
- NCI:C3867
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:276870001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0238122
- Exact Synonym (Disease Ontology)
- cancer of the fallopian tube
- Exact Synonym (Disease Ontology)
- carcinoma of fallopian tube
- Exact Synonym (Disease Ontology)
- fallopian tube Ca
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030394